EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis

HyungSub Jin, HyungJu Jin, Kyung-Soo Suk, Byung Ho Lee, Si Young Park, Hak-Sun Kim, Seong-Hwan Moon, Sub-Ri Park, Namhoo Kim, Jae Won Shin, Ji-Won Kwon

Osteoporosis International · 2025

DOI: 10.1007/s00198-025-07661-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Osteoporosis International, 2025. Verfasst von HyungSub Jin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Yonsei University College of Medicine, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea. Hauptthemen laut MEDLINE: Spinal Fractures, Osteoporotic Fractures, Bone Density Conservation Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 95 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporotic vertebral fractures (OVFs) increase mortality and impair patients' quality of life. Previous studies have focused on the effects of anti-osteoporosis drugs for primary fracture prevention; however, their role in secondary prevention remains insufficiently explored. Since refractures lead to more serious health issues and are strongly associated with prior fractures and low bone mineral density (BMD), effective treatment strategies for patients with existing OVFs are crucial. A systematic search was conducted using PubMED, Cochrane Library, and EMBASE according to PRISMA guidelines. Two reviewers independently selected and assessed relevant studies. A meta-analysis was conducted to examine the effects of anti-osteoporosis medications on refracture prevention in adult patients with existing OVFs. A total of 33 studies were included in the analysis. Compared to the control, bisphosphonates were associated with lower subsequent vertebral fracture (VF) rates at 1 year [OR = 0.29, 95% CI = 0.20-0.43], 3 years [OR = 0.51, 95% CI = 0.42-0.62], and final follow-up [OR = 0.35, 95% CI = 0.26-0.48]; greater BMD percent changes at 1 year [MD = 3.65, 95% CI = 2.63-4.67], 2 years [MD = 5.39, 95% CI = 3.87-6.92], and 3 years [MD = 5.44, 95% CI = 4.38-6.51]; improved VAS scores at 6 months [MD (95% CI) = -0.41 (-0.67, -0.14)] and 12 months [MD (95% CI) = -0.92 (-1.25, -0.59)]; and improved ODI scores at 12 months [SMD (95% CI) = -1.89 (-3.07, -0.71)]. Teriparatide was associated with lower subsequent VF rates compared to the control [OR = 0.39, 95% CI = 0.16-0.97] and bisphosphonates [OR = 0.41, 95% CI = 0.30-0.56], and led to improved VAS scores at 3 months [MD (95% CI) = -1.41 (-2.47, -0.35)] compared to bisphosphonates. Vitamin D improved RMDQ scores at 3 months [MD (95% CI) = -1.59 (-2.88, -0.31)] compared to the control. Additionally, romosozumab was associated with lower subsequent VF rates compared to bisphosphonates in patients undergoing vertebral augmentation [OR = 0.21, 95% CI = 0.09-0.51]. Teriparatide may be considered a preferred option for secondary fracture prevention in patients with OVFs. Romosozumab demonstrated potential benefit in patients after vertebral augmentation, although the supporting evidence is limited. Bisphosphonates may remain a reasonable alternative when anabolic agents are unavailable or contraindicated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal FracturesOsteoporotic FracturesBone Density Conservation AgentsHumansSecondary PreventionOsteoporosisBone DensityDiphosphonatesRecurrence

Stichwörter der Autor:innen

BisphosphonateDenosumabOsteoporosisRefractureRomosozumabTeriparatideVertebral fractureVitamin D

Substanzen

Bone Density Conservation AgentsDiphosphonates

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, Yonsei University College of Medicine, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea.
  • Department of Medicine, Yonsei University College of Medicine, Yonsei University, 50-1 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea.
  • Department of Orthopedic Surgery, Yonsei University College of Medicine, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea. kwonjjanng@yuhs.ac.

Zitieren

APA

Jin, H., Jin, H., Suk, K. S., Lee, B. H., Park, S. Y., Kim, H. S., Moon, S. H., Park, S. R., Kim, N., Shin, J. W., & Kwon, J. W. (2025). Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis. Osteoporosis International. https://doi.org/10.1007/s00198-025-07661-4

Vancouver

Jin H, Jin H, Suk KS, Lee BH, Park SY, Kim HS, et al. Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis. Osteoporosis International. 2025. doi:10.1007/s00198-025-07661-4

BibTeX
@article{Jin2025,
  author = {Jin, HyungSub and Jin, HyungJu and Suk, Kyung-Soo and Lee, Byung Ho and Park, Si Young and Kim, Hak-Sun and Moon, Seong-Hwan and Park, Sub-Ri and Kim, Namhoo and Shin, Jae Won and Kwon, Ji-Won},
  title = {Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis},
  journal = {Osteoporosis International},
  year = {2025},
  doi = {10.1007/s00198-025-07661-4}
}
Kostenlos starten →